Cortria Corporation   Report issue

For profit Phase 1 Phase 3
Founded: Boston MA United States (2005)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2007
NCT00758303
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

n-methylnicotinamide chloride (4 trials)

Drugs in Phase 1 Trials (1)

niacin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperlipidemia, Familial Combined (Phase 2)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 2)

Hypertriglyceridemia (Phase 2)

Malnutrition (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2